Ku saabsan-kansarka / daaweynta / tijaabooyinka-kiliinikada / kansarka xiniinyaha
Tijaabooyin caafimaad oo lagu daaweynayo kansarka xiniinyaha
Tijaabooyinka 1-4 ee 4
Nivolumab iyo Ipilimumab oo lagu daaweynayo bukaanada leh burooyinka dhifka ah
Wejigan 2aad tijaabinta tijaabada nivolumab iyo ipilimumab ee lagu daaweynayo bukaannada qaba burooyinka dhifka ah. Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab iyo ipilimumab, ayaa ka caawin kara habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin ku yeelan karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Tijaabadani waxay uqortaa kaqeybgalayaasha koorsooyinka soo socda oo ku saleysan xaalad: 1. Burooyinka Epithelial ee sanka, sanka, nasopharynx: A) Cudurka unugyada qanjirada 'squamous cell carcinoma' oo leh noocyo sanka sanka ah, sanka, iyo nasopharynx iyo trachea (marka laga reebo laryngeal, kansarka nasopharyngeal [NPC] , iyo kansarka unugyada unugyada ee madaxa iyo qoorta [SCCHN]) B) Adenocarcinoma iyo noocyada sanka, sanka, iyo nasopharynx (oo uxiran soo uruurinta 07/27/2018) 2. Burooyinka Epithelial ee qanjidhada waaweyn ee candhuufta (waxay uxiran yihiin kuleel 03 / 20/2018) 3. Burooyinka nooca qanjidhada candhuufta ee madaxa iyo qoorta, dibnaha, hunguriga, caloosha, neef mareenka iyo sambabka, naaska iyo meel kale (oo u xidhan ku uruursiga) 4. Kansarka aan kala sooca lahayn ee marinka caloosha iyo caloosha (GI) 5. Adenocarcinoma oo leh noocyo xiidmaha yar yar 05/10/2018) 6. Kansarka unugyada 'squamous cell carcinoma' oo leh noocyo kala duwan oo ah habka 'GI tract' (caloosha yar ee caloosha, xiidanka, malawadka, xammeetida) (oo u xiran isku soo uruurinta 10/17/2018) 7. Fibromixoma iyo adenocarcinoma mucinous fasal hoose ah (pseudomixoma peritonei) lifaaqa iyo ugxansidaha (uxiranyahay aruurinta 03/20/2018) 8. burooyinka qanjidhada oo dhif ah oo ay kujiraan kansarka unugyada 'acinar cell carcinoma', 'mucinous cystadenocarcinoma' ama 'serous cystadenocarcinoma'. Pancreatic adenocarcinoma uma qalmo 9. Intrahepatic cholangiocarcinoma (waxaa loo xiray aruurinta 03/20/2018) 10. Cudurka 'Extrahepatic cholangiocarcinoma' iyo xuubka dheecaanka 'bile duct' (waxaa loo xiray aruurinta 03/20/2018) 11. Kansarka Sarcomatoid ee sambabka 12. Bronchoalveolar carcinoma lung. Xaaladdaan waxaa sidoo kale loo yaqaan adenocarcinoma in situ, adenocarcinoma yar yar, lepidic adenocarcinoma lepidic, ama adenocarcinoma mucinous invasive 13. Burooyinka aan epithelial ee ugxan sidaha: A) Burooyinka unugyada jeermiska ee ugxansidaha B) Mullerian buro isku dhafan iyo adenosarcoma inuu ku soo boodo 03/30/2018) 14. buro Trophoblastic: A) Choriocarcinoma (waxaa loo xiray inuu ahaado) 15. Carcinoma unugga ku meelgaarka ah oo aan ka aheyn kan kalyaha, miskaha, kaadi mareenka, ama kaadiheysta (u xiran inuu ku soo ururo) 16. Buro unugyada tijaabooyinka iyo burooyinka jeermiska dheeriga ah: A) Seminoma iyo kansarka xudunta galmada ee xiniinyaha B) Buro aan seminomatous C) Teratoma oo leh isbedel xun (uxiran isku soo aruurinta) 17.
Goobta: 895 goobood
Kormeerka firfircoon, Bleomycin, Carboplatin, Etoposide, ama Cisplatin ee lagu daaweynayo bukaanka carruurta iyo qaangaarka ee leh burooyinka Germ Cell Qeybtan III waxay tijaabineysaa sida ugu wanaagsan ee kormeerka firfircoon, bleomycin, karboplatin, etoposide, ama cisplatin ay u shaqeeyaan daaweynta carruurta iyo bukaanka qaangaarka leh burooyinka unugyada jeermiska. . Lasocodka firfircoon wuxuu ka caawin karaa dhakhaatiirta inay la socdaan maadooyinka leh burooyinka unugyada jeermiska ee halista yar ka dib marka laga saaro burooyinka. Daawooyinka loo isticmaalo kiimoteraabiga, sida bleomycin, karboplatin, etoposide, iyo cisplatin, waxay u shaqeeyaan siyaabo kala duwan si ay u joojiyaan koritaanka unugyada burooyinka, iyagoo dilaya unugyada, iyaga oo ka joojinaya inay kala baxaan, ama ka joojiyaan faafitaanka. Goobta: 460 goobood
Inotuzumab Ozogamicin iyo Daaweynta Kiimikada Daaweynta Kadib ee Lagu Daaweynayo Bukaannada Khatarta Sare leh ee B-ALL, Isku-darka Phenotype Acute Leukemia, iyo B-LLy
Marxaladan tijaabada ah ee wajiga III waxay daraasad ku sameyneysaa in inotuzumab ozogamicin lagu daro kiimikada daaweynta kadib-soo-kicinta ee loogu talagalay bukaannada qaba Khatarta Sare ee B-cell Acute Lymphoblastic Leukemia (B-ALL) waxay hagaajineysaa natiijooyinka. Tijaabadani waxay sidoo kale darsaysaa natiijooyinka bukaanada qaba cudurka leukemia daran ee loo yaqaan 'phenotype daran leukemia (MPAL), iyo B-lymphoblastic lymphoma (B-LLy) markii lagu daaweeyay DHAMMAAN daaweynta iyada oo aan la helin inotuzumab ozogamicin. Inotuzumab ozogamicin waa antibiyootiko monoclonal ah, oo loo yaqaan inotuzumab, oo ku xiran nooc ka mid ah daaweynta kiimiko ee loo yaqaan calicheamicin. Inotuzumab waxay ku dhegan tahay unugyada kansarka qaab bartilmaameed ah waxayna gaarsiisaa calicheamicin si ay u disho. Daawooyinka kale ee loo isticmaalo daaweynta kemotherabi, sida cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, iyo pegaspargase waxay u shaqeeyaan siyaabo kala duwan si ay u joojiyaan koritaanka unugyada kansarka, iyaga oo dilaya unugyada, iyaga oo ka joojinaya kala qaybinta, ama ka joojinta faafitaanka. Tijaabadani waxay sidoo kale baran doontaa natiijooyinka bukaanada qaba isku-dhafka 'leukemia daran' ee loo yaqaan 'MPAL' iyo faafinta B lymphoblastic lymphoma (B-LLy) markii lagu daaweeyay khatar sare DHAMMAAN daaweynta. Ujeeddada guud ee daraasaddan ayaa ah in la fahmo haddii lagu daro inotuzumab ozogamicin heerka daryeelka kiimoteraabiga ay ilaalineyso ama hagaajinayso natiijooyinka Halis Sare ee B-cell Acute Lymphoblastic Leukemia (HR B-ALL). Qaybta koowaad ee daraasadda waxaa ka mid ah labada weji ee ugu horreeya daaweynta: Soo-kicinta iyo Isugeynta. Qeybtaan waxay aruurin doontaa macluumaadka ku saabsan cudurka leukemia, iyo sidoo kale saameynta daaweynta bilowga ah, si loogu kala saaro bukaanada kooxaha daweynta isku dhafka kadib. Qeybta labaad ee daraasaddan, bukaanku waxay heli doonaan inta ka hartay wareegyada kiimikada (dayactirka ku-meelgaarka ah I, dib-u-xoojinta dib-u-dhiska, dayactirka ku-meelgaarka ah II, dayactirka), iyadoo bukaanada qaar loo kala saaray inay helaan inotuzumab. Ujeeddooyinka kale ee daraasaddan waxaa ka mid ah baaritaanka haddii lagu daaweynayo ragga iyo dumarka labadaba muddada isku midka ah ee daaweynta kiimikada ayaa haysa natiijooyinka ragga horay loogu daaweeyay sanad dheeraad ah marka loo eego gabdhaha, iyo sidoo kale in la qiimeeyo siyaabaha ugu wanaagsan ee looga caawiyo bukaanada inay u hoggaansamaan afka nidaamyada daaweynta kiimikada. Ugu dambeyntiina, daraasaddan ayaa noqon doonta tii ugu horreysay ee lagu dabagalo natiijooyinka maaddooyinka leh faafitaanka B-cell Lymphoblastic Leukemia (B LLy) ama Mixed Phenotype Acute Leukemia (MPAL) markii lagu daaweeyay B-ALL chemotherapy. bukaanku waxay heli doonaan inta ka hartay wareegyada kiimoteraabiga (dayactirka kumeelgaarka ah I, dib udhaca xoojinta, dayactirka ku meel gaarka ah II, dayactirka), iyadoo bukaanada qaar loo kala saaray inay helaan inotuzumab Ujeeddooyinka kale ee daraasaddan waxaa ka mid ah baaritaanka haddii lagu daaweynayo ragga iyo dumarka labadaba muddada isku midka ah ee daaweynta kiimikada ayaa haysa natiijooyinka ragga horay loogu daaweeyay sanad dheeraad ah marka loo eego gabdhaha, iyo sidoo kale in la qiimeeyo siyaabaha ugu wanaagsan ee looga caawiyo bukaanada inay u hoggaansamaan afka nidaamyada daaweynta kiimikada. Ugu dambeyntiina, daraasaddan ayaa noqon doonta tii ugu horreysay ee lagu dabagalo natiijooyinka maaddooyinka leh faafitaanka B-cell Lymphoblastic Leukemia (B LLy) ama Mixed Phenotype Acute Leukemia (MPAL) markii lagu daaweeyay B-ALL chemotherapy. bukaanku waxay heli doonaan inta ka hartay wareegyada kiimoteraabiga (dayactirka ku-meelgaarka ah I, dib-u-xoojinta dib-u-dhiska, dayactirka ku-meelgaarka ah II, dayactirka), iyadoo bukaannada qaar loo kala saaray inay helaan inotuzumab. Ujeeddooyinka kale ee daraasaddan waxaa ka mid ah baaritaanka haddii lagu daaweynayo ragga iyo dumarka labadaba muddada isku midka ah ee daaweynta kiimikada ayaa haysa natiijooyinka ragga horay loogu daaweeyay sanad dheeraad ah marka loo eego gabdhaha, iyo sidoo kale in la qiimeeyo siyaabaha ugu wanaagsan ee looga caawiyo bukaanada inay u hoggaansamaan afka nidaamyada daaweynta kiimikada. Ugu dambeyntiina, daraasaddan ayaa noqon doonta tii ugu horreysay ee lagu dabagalo natiijooyinka maaddooyinka leh faafitaanka B-cell Lymphoblastic Leukemia (B LLy) ama Mixed Phenotype Acute Leukemia (MPAL) markii lagu daaweeyay B-ALL chemotherapy. Ujeeddooyinka kale ee daraasaddan waxaa ka mid ah baaritaanka haddii lagu daaweynayo ragga iyo dumarka labadaba muddada isku midka ah ee daaweynta kiimikada ayaa haysa natiijooyinka ragga horay loogu daaweeyay sanad dheeraad ah marka loo eego gabdhaha, iyo sidoo kale in la qiimeeyo siyaabaha ugu wanaagsan ee looga caawiyo bukaanada inay u hoggaansamaan afka Nidaamka kiimoteraabiga. Ugu dambeyntiina, daraasaddan ayaa noqon doonta tii ugu horreysay ee lagu dabagalo natiijooyinka maaddooyinka leh faafitaanka B-cell Lymphoblastic Leukemia (B LLy) ama Mixed Phenotype Acute Leukemia (MPAL) markii lagu daaweeyay B-ALL chemotherapy. Ujeeddooyinka kale ee daraasaddan waxaa ka mid ah baaritaanka haddii lagu daaweynayo ragga iyo dumarka labadaba muddada isku midka ah ee daaweynta kiimikada ayaa haysa natiijooyinka ragga horay loogu daaweeyay sanad dheeraad ah marka loo eego gabdhaha, iyo sidoo kale in la qiimeeyo siyaabaha ugu wanaagsan ee looga caawiyo bukaanada inay u hoggaansamaan afka nidaamyada daaweynta kiimikada. Ugu dambeyntiina, daraasaddan ayaa noqon doonta tii ugu horreysay ee lagu dabagalo natiijooyinka maaddooyinka leh faafitaanka B-cell Lymphoblastic Leukemia (B LLy) ama Mixed Phenotype Acute Leukemia (MPAL) markii lagu daaweeyay B-ALL chemotherapy.
Goobta: 189 goobood
Dardargelinta ama Heerka Daaweynta Daaweynta Daaweynta Daaweynta Daaweynta Daaweynta Daaweynta Bukaanka ee Bukaannada Dhexe ama Khatarta Khatarta ah
Wejigan tijaabada ah ee la kala soocay III ayaa daraasad ku sameeya sida wanaagsan ee jadwalka loo dardar geliyey ee loo yaqaan 'bleomycin sulfate, etoposide phosphate, iyo cisplatin (BEP) chemotherapy ayaa u shaqeeya marka la barbar dhigo jadwalka caadiga ah ee daaweynta' BEP chemotherapy 'ee lagu daaweynayo bukaannada qaba burooyinka unugyada jeermiska dhexe ama kuwa halista ah ee ku faafay kuwa kale meelaha jirka (metastatic). Daawooyinka loo isticmaalo kiimoteraabiga, sida bleomycin sulfate, etoposide phosphate, iyo cisplatin, waxay u shaqeeyaan siyaabo kala duwan si loo joojiyo koritaanka unugyada burooyinka, iyadoo la dilayo unugyada, iyadoo laga joojinayo inay kala baxaan, ama laga joojiyo faafitaanka. Bixinta daaweynta kemotherabi ee BEP si dhakhso leh, ama "xawaareyn" ah ayaa laga yaabaa inay sifiican ula shaqeyso waxyeelo yar oo ka timaadda daaweynta bukaanka qaba burooyinka unugyada unugyada jeermiska dhexe ama kuwa saboolka ah ee saboolka marka la barbar dhigo jadwalka caadiga ah.
Goobta: 139 goobood
Daar faallada is cusboonaysiinta